158 related articles for article (PubMed ID: 31044025)
1. Prognostic significance of aberrant CD5 expression in B-cell leukemia.
Jaseb K; Purrahman D; Shahrabi S; Ghanavat M; Rezaeean H; Saki N
Oncol Rev; 2019 Jan; 13(1):400. PubMed ID: 31044025
[TBL] [Abstract][Full Text] [Related]
2. Clinical and prognostic significance of aberrant T-cell marker expression in 225 cases of de novo diffuse large B-cell lymphoma and 276 cases of other B-cell lymphomas.
Tsuyama N; Ennishi D; Yokoyama M; Baba S; Asaka R; Mishima Y; Terui Y; Hatake K; Takeuchi K
Oncotarget; 2017 May; 8(20):33487-33500. PubMed ID: 28380441
[TBL] [Abstract][Full Text] [Related]
3. [Bone marrow immunophenotypes of 112 cases of lymphoid system malignant diseases].
Ling JY; Sun XF; Yan SL; He LR; Zhen ZJ; Xia Y
Ai Zheng; 2007 Apr; 26(4):418-22. PubMed ID: 17430665
[TBL] [Abstract][Full Text] [Related]
4. [Application of flow cytometry in the differential diagnosis of lymphoma/leukemia with aberrant antigen expression].
Xia CQ; Chen SL; Qi M; Xu XF
Zhonghua Bing Li Xue Za Zhi; 2004 Dec; 33(6):532-5. PubMed ID: 15634450
[TBL] [Abstract][Full Text] [Related]
5. CD5-positive follicular lymphoma: prognostic significance of this aberrant marker?
Mayson E; Saverimuttu J; Cartwright K
Intern Med J; 2014 Apr; 44(4):417-22. PubMed ID: 24754692
[TBL] [Abstract][Full Text] [Related]
6. Clinical and biological significance of de novo CD5+ diffuse large B-cell lymphoma in Western countries.
Xu-Monette ZY; Tu M; Jabbar KJ; Cao X; Tzankov A; Visco C; Nagarajan L; Cai Q; Montes-Moreno S; An Y; Dybkaer K; Chiu A; Orazi A; Zu Y; Bhagat G; Richards KL; Hsi ED; Choi WW; van Krieken JH; Huh J; Ponzoni M; Ferreri AJ; Zhao X; Møller MB; Farnen JP; Winter JN; Piris MA; Miranda RN; Medeiros LJ; Young KH
Oncotarget; 2015 Mar; 6(8):5615-33. PubMed ID: 25760242
[TBL] [Abstract][Full Text] [Related]
7. Detection of CD5 in B-cell chronic lymphoproliferative diseases by flow cytometry: a strong expression in B-cell chronic lymphocytic leukemia.
Cavalcanti Júnior GB; Sales VS; Cavalcanti e Silva DG; Lopes MC; Paiva Ade S; da Fonseca HE; do Nascimento Júniors FF; Fernandes MZ
Acta Cir Bras; 2005; 20 Suppl 1():101-7. PubMed ID: 16186976
[TBL] [Abstract][Full Text] [Related]
8. Incidence of phenotypic aberrations in a series of 467 patients with B chronic lymphoproliferative disorders: basis for the design of specific four-color stainings to be used for minimal residual disease investigation.
Sánchez ML; Almeida J; Vidriales B; López-Berges MC; García-Marcos MA; Moro MJ; Corrales A; Calmuntia MJ; San Miguel JF; Orfao A
Leukemia; 2002 Aug; 16(8):1460-9. PubMed ID: 12145686
[TBL] [Abstract][Full Text] [Related]
9. Clinical Significance of
Ting CY; Chang KM; Kuan JW; Sathar J; Chew LP; Wong OJ; Yusuf Y; Wong L; Samsudin AT; Pana MNBM; Lee SK; Gopal NSR; Puri R; Ong TC; Bahari SK; Goh AS; Teoh CS
Int J Med Sci; 2019; 16(4):556-566. PubMed ID: 31171907
[No Abstract] [Full Text] [Related]
10. Analysis of the immunoglobulin heavy chain gene variable region of CD5-positive diffuse large B-cell lymphoma.
Nakamura N; Hashimoto Y; Kuze T; Tasaki K; Sasaki Y; Sato M; Abe M
Lab Invest; 1999 Aug; 79(8):925-33. PubMed ID: 10462030
[TBL] [Abstract][Full Text] [Related]
11. Clinical impact of CD5 expression in Korean patients with diffuse large B-cell lymphoma.
Kim HY; Jang MA; Kim HJ; Kim SJ; Kim WS; Kim SH
Blood Res; 2017 Sep; 52(3):193-199. PubMed ID: 29043234
[TBL] [Abstract][Full Text] [Related]
12. Intravascular large B-cell lymphoma: the CD5 antigen is expressed by a subset of cases.
Khalidi HS; Brynes RK; Browne P; Koo CH; Battifora H; Medeiros LJ
Mod Pathol; 1998 Oct; 11(10):983-8. PubMed ID: 9796727
[TBL] [Abstract][Full Text] [Related]
13. Quantitative analysis of CD79b, CD5 and CD19 in mature B-cell lymphoproliferative disorders.
Cabezudo E; Carrara P; Morilla R; Matutes E
Haematologica; 1999 May; 84(5):413-8. PubMed ID: 10329919
[TBL] [Abstract][Full Text] [Related]
14. Clinicopathologic significance and therapeutic implication of de novo CD5+ diffuse large B-cell lymphoma.
Tang H; Zhou H; Wei J; Liu H; Qian W; Chen X
Hematology; 2019 Dec; 24(1):446-454. PubMed ID: 31072235
[TBL] [Abstract][Full Text] [Related]
15. Secondary CD5+ diffuse large B-cell lymphoma not associated with transformation of chronic lymphocytic leukemia/small lymphocytic lymphoma (Richter syndrome).
Maeshima AM; Taniguchi H; Nomoto J; Maruyama D; Kim SW; Watanabe T; Kobayashi Y; Tobinai K; Matsuno Y
Am J Clin Pathol; 2009 Mar; 131(3):339-46. PubMed ID: 19228640
[TBL] [Abstract][Full Text] [Related]
16. Prognostic impact of CD5 expression in diffuse large B-cell lymphoma in patients treated with rituximab-EPOCH.
Thakral B; Medeiros LJ; Desai P; Lin P; Yin CC; Tang G; Khoury JD; Hu S; Xu J; Loghavi S; Hu B; Oki Y; Li S
Eur J Haematol; 2017 Apr; 98(4):415-421. PubMed ID: 28039906
[TBL] [Abstract][Full Text] [Related]
17. CD5 Positive B Lymphoblastic Leukemia: Report of a Case with Review of Literature.
Sreedharanunni S; Kumar N; Khadwal A
Indian J Hematol Blood Transfus; 2016 Jun; 32(Suppl 1):1-4. PubMed ID: 27408342
[TBL] [Abstract][Full Text] [Related]
18. [Clinicopathologic features and expression of OCT4 protein in testicular diffuse large B cell lymphoma].
Chen YP; Zhu WF; Chen LF; Lu JP; He TM; Fu WD; Xu CW; Chen G
Zhonghua Bing Li Xue Za Zhi; 2017 Jun; 46(6):383-387. PubMed ID: 28591984
[No Abstract] [Full Text] [Related]
19. [Clinicopathological features of de novo CD5-positive diffuse large B-cell lymphoma].
Fan Y; Dong L; OUYang BS; Xu HM; Zheng SF; Wang AR; Wang CF
Zhonghua Bing Li Xue Za Zhi; 2020 May; 49(5):448-453. PubMed ID: 32392928
[No Abstract] [Full Text] [Related]
20. Analysis of chromosomal imbalances in de novo CD5-positive diffuse large-B-cell lymphoma detected by comparative genomic hybridization.
Karnan S; Tagawa H; Suzuki R; Suguro M; Yamaguchi M; Okamoto M; Morishima Y; Nakamura S; Seto M
Genes Chromosomes Cancer; 2004 Jan; 39(1):77-81. PubMed ID: 14603444
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]